

# GammaTile™ Therapy | STaRT

PATIENT GUIDE

A head STaRT  
in the fight  
against recurrent  
brain tumors



The right treatment. At the right time. In the right place.

GammaTile Therapy is a safe and effective, surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors.

While cancer treatment with implantable radiation therapy is not new, GammaTile Therapy is the first treatment specifically designed for use in the brain. And unlike other radiation therapies, there's no treatment delay. Immediately after removing the brain tumor, your neurosurgeon places GammaTile(s) in the area that's most at risk for recurrence.

GammaTile Therapy gets a head STaRT on fighting tumor cells and eliminates the need for traditional repeat radiation treatments and hospital visits, so you can focus on what matters most—healing.

For more information about GammaTile Therapy and if it might be right for you, please speak with your healthcare team.



The design of GammaTile keeps the radiation source from directly contacting the brain tissue while it delivers treatment to tumor cells.



**GammaTile Therapy | STaRT.**  
**TOUGH ON THE TUMOR.**  
**EASIER ON YOU AND YOUR CAREGIVERS.**


- Your neurosurgeon places GammaTile(s) precisely where and when treatment will help the most—immediately after tumor removal.
- Radiation is focused right where it's needed and away from healthy brain tissue.<sup>1</sup>
- Most patients experienced fewer side effects when compared to patients who received other, more traditional repeat radiation treatments.<sup>1-3</sup>
- There is no need for an extra hospital stay or to travel for additional, ongoing radiation treatments.



**IMMEDIATE TREATMENT IS  
 POWERFUL TREATMENT.**

- Taken as a whole group (across all tumor types in the clinical study), patients who received surgery plus GammaTile™ Therapy had approximately a 2x improvement in median time to tumor recurrence compared to their most recent prior same site treatment.<sup>1,\*</sup>
- The median time to surgical-site brain tumor recurrence was 19.9 months, a 9.7-month improvement across all tumor types in the clinical study.<sup>1,\*</sup>

**~2X IMPROVEMENT | ACROSS ALL TUMOR  
 TYPES IN THE STUDY**



- ~2x improvement vs previous treatments in median time to recurrence.

\* Tumor types in the clinical study were high-grade gliomas, meningiomas, and brain metastases.

## TREATMENT CONSIDERATIONS.

GammaTile is intended to deliver radiation therapy for patients with recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s).

GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

**Ask your physician if GammaTile Therapy might be right for you.**

## REFERENCES

1. Data on file, GT Medical Technologies, Inc. 2. Lin AJ, Hui C, Dahiya S, et. al. Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation. *Int J Radiation Oncol Biol Phys*. 2018;102(1):194-203. 3. Scossianti S, Franncolini G, Carta G, et al. Re-irradiation as salvage in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions. *Crit Rev Oncology*. 2018;126:89-91.



**IMPROVING THE LIVES  
OF PATIENTS WITH BRAIN TUMORS**

©2019 GT Medical Technologies, Inc. | All rights reserved  
GammaTile is a registered trademark of GT Medical Technologies, Inc.  
MKT-007B

**gtmedtech.com**

1809 South Holbrook Lane, Suite 107  
Tempe, AZ 85281  
833.662.0044